A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CAP / controlled attenuation parameter

[Related PubMed/MEDLINE]
Total Number of Papers: 184
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CAP  (>> Co-occurring Abbreviation)
Long Form:   controlled attenuation parameter
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. AUROCs, CI, LSMs
2019 Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. NAFLD
2019 Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. cACLD, cACLD, DC, DC, HR, TE
2019 Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients. ROC, TE
2019 Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. LB, MRI-PDFF, NAFLD, NASH
2019 Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. LSM, NAFLD
2019 Fibroblast Growth Factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. FGF-21, HIV
2019 Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study. BMI, Hp, NAFLD, NAS, NASH, TC
2019 Hepatic steatosis and patients with inflammatory bowel disease: when transient elastography makes the difference. FLI, HS, HSI, IBD
10  2019 Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. DAA, LDL-C
11  2019 Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center. NAFLD, TE
12  2019 Is Fasting Necessary for Individuals With Nonalcoholic Fatty Liver Disease to Undergo Vibration-Controlled Transient Elastography? LSM
13  2019 Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography. AOR, BMI, CI, IBD, NAFLD, TE
14  2019 Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. CK18, HCV, NAFLD, TE
15  2019 The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients: A biopsy-controlled study. ARFI, NAFLD
16  2019 The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience. GHBT, NAFLD, NASH, SIBO, TE
17  2018 Advances in diagnosis of chronic liver diseases in pediatric patients. CLD, LSM, NAFLD, TE
18  2018 Association Between Hepatic Steatosis, Measured by ControlledAttenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. CHB
19  2018 Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? ---
20  2018 Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. DAA, EOT, HCV, SVR, TE
21  2018 Clinical implications of controlled attenuation parameter in a health check-up cohort. AST, BMI, CI, OR, US
22  2018 Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification. AUC
23  2018 Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality. OR
24  2018 Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. MetS
25  2018 Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. CFLD, LSM, PHTN, TE
26  2018 Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values. IQR
27  2018 Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C. CHC, DAAs
28  2018 Effects of Gene Variants Controlling Vitamin D Metabolism and Serum Levels on Hepatic Steatosis. CYP2R1, DHCR7, Gc
29  2018 Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. DAA, HCV
30  2018 Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma. CHC, HCC
31  2018 Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. LS, NAFLD
32  2018 Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. HCV, SVR
33  2018 Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan. NNMT, PCR-RFLP, SNPs
34  2018 Grip Strength Moderates the Association between Anthropometric and Body Composition Indicators and Liver Fat in Youth with an Excess of Adiposity. NAFLD, VAT, WC, WHtR
35  2018 Haptoglobin Genotype and VitaminE Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. app, CRN, Hp, NAS, NASH, RCT, TE
36  2018 Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. NAFLD
37  2018 Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. CHB, CVR, HBeAg, HCC, HR, HS, TE
38  2018 Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. CHB, LS, NAFLD
39  2018 Liver disease in adults with alpha1-antitrypsin deficiency. A1AD, CSPH
40  2018 Liver Fat Content and Body Fat Distribution in Youths with Excess Adiposity. BMI, CRF, DXA, NAFLD, VAT
41  2018 Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. DAAs, HCV, IFN, LDL-C, sdLDL-C, SVR
43  2018 MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis. IQR, MR, NAFLD, PDFF, ROC
44  2018 Neutrophil-lymphocyte ratio and mean platelet volume as predictive factors for liver fibrosis and steatosis in patients with chronic hepatitisB. ---
45  2018 Optimal cutoff value for assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting. ---
46  2018 Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. AUROC, CI, IQR, MRI-PDFF, NAFLD
47  2018 Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. LSM
48  2018 Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter. HS, LB
49  2018 Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. ART, AZT, CI, LSM, OR
50  2018 Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP). CHC, TE
51  2018 Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. ABCD, LSM, NAFLD
52  2018 Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. FLI, LS, NAFLD
53  2018 Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. cACLD, LSM
54  2018 Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease. AUROC, CK-18, NAFLD, US
55  2018 Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. BMI, cART, HIV, HS
56  2018 Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus. BMI, LSV, T2DM, WHR
57  2018 Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. AOR, CK-18, HOMA-IR, NASH, TE
58  2018 Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. DAA, EOT, LS, SVR
59  2018 The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. CK18, NAFLD, NASH, PCOS
60  2018 The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. UGAP
61  2018 The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients. MetS, NAFLD
62  2018 The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients. LT, TE
63  2018 Usefulness of controlled attenuation parameter for detecting increased arterial stiffness in general population. CAVI, OR
64  2018 Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. CI, LSM, NAFLD
65  2017 A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. AUROCs, CHB, CIs, HSI
66  2017 A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. AUROC, CHB, DBP, FL, LR, T2DM
67  2017 A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. FBG
68  2017 A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis. AUROCs, CI, HSI
69  2017 Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. CI, CKD, LSM, NAFLD, OR
70  2017 Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease. DNL, NAFLD, NAMPT
71  2017 Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults on their health check-up. CI, CKD, eGFR, FLI, NAFLD, OR
72  2017 Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. ELF, LSM, MR, NAFLD, TE
73  2017 Atherosclerosis is associated with a higher risk of hepatic steatosis in HIV-infected patients. AT, CD, CIMT, HS
74  2017 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. EFV, HIV, NAFLD, RAL
75  2017 Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. ---
76  2017 Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. LS, LSM
77  2017 Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan: A Comparative Study with the M Probe and Liver Biopsy. LB
78  2017 Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults. HCV, MRS, MRS-HS
79  2017 Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease. NAFLD
80  2017 Controlled attenuation parameter using the FibroScan XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. LSM, NAFLD
81  2017 Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. cfDNA, NAFLD
82  2017 Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease. BMI, CI, CLD, NAFLD, OR
83  2017 Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. CI, FLD, FTO, SNPs, T2DM
84  2017 Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study. ---
85  2017 Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART). cART, cART, SNPs
86  2017 Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. aHR, CI, HCV, HIV, HS, LIVEHIV, LSM
87  2017 High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal. 2D-SWE, TE
88  2017 High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatits B. CHB
89  2017 Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. LSM, NAFLD
90  2017 Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. ---
91  2017 Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. NAFLD, T2D
92  2017 Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. AUROC, CI, MRE, MRI, MRI-PDFF, NAFLD, TE
93  2017 Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). MRE, MRI, NAFLD, TE
94  2017 Non-invasive diagnosis of hepatic steatosis. CT, MRI
95  2017 Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. BMI, FLI, HSI, US
96  2017 Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. CI, LSM, MHNO, MHO, MUNO, MUO, NAFLD, ORs, TE
97  2017 Potential impact of screening for fatty liver disease by transient elastography with liver stiffness and controlled attenuation parameter measurements: a pilot study. LSM
98  2017 Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. ACS, CVA, CVE, HCC, LRE, LSM, NAFLD, TE
99  2017 Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study. ALT, AUS, HCC, LSM, TE
100  2017 Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. CAD, NAFLD, TE